“…Loss of CADM1 expression has been described in many malignancies, including liver, pancreatic, breast, brain and prostate cancers, particularly in those showing invasion or metastasis (Kuramochi et al, 2001;Fukuhara et al, 2002;Jansen et al, 2002;Houshmandi et al, 2006;Heller et al, 2007). Promoter hypermethylation was reported to account for downregulation of CADM1 in several human cancers (Murakami, 2005;Ehrlich et al, 2006;Kikuchi et al, 2006;Worsham et al, 2006). Moreover, high expression levels of CADM1 from a recombinant adenovirus vector were shown to inhibit cell proliferation and to induce apoptosis in the non-small cell lung cancer cell line A549 (Mao et al, 2004).…”